0.6617USD-0.56%Mkt Cap: 17.76M USDP/E: —Last update: 2026-06-01
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment o…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap17.76M USD
Enterprise Value21.74M USD
Revenue (TTM)5.61M USD
Gross Profit4.49M USD
Net Income (TTM)-37.43M USD
Revenue/Share0.3110 USD
Last Price0.6617 USD
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees23
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.81
PEG—
EV/EBITDA-0.40
EV/Revenue3.87
P/S3.20
P/B0.18
EPS (TTM)-2.14
EPS (Forward)-0.81
52W Range
0.47609% of range2.480
52W High2.480 USD
52W Low0.4760 USD
Profitability
Gross Margin80.07%
Oper. Margin-1827.78%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-55.42%
ROA-28.59%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-26.55M USD
CapEx (TTM)—
FCF Margin-596.27%
FCF Yield-188.38%
Net Debt-3.78M USD
Net Debt/EBITDA0.07
Balance Sheet
Debt/Equity0.03
Current Ratio0.58
Quick Ratio0.10
Book Value/Sh3.573 USD
Cash/Share0.1670 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJun 9, 2017
Splits
Last Split1:25
Split DateNov 26, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)4.000 USD
Target Range4.000 USD – 4.000 USD
# Analysts1
Ownership
Shares Out.27.45M
Float26.96M
Insiders1.80%
Institutions3.63%
Short Interest
Short Ratio5.3d
Short % Float19.15%
Short % Out.18.81%
Shares Short5.16M
Short (prev mo.)4.00M
Technical
SMA 500.7397 (-10.5%)
SMA 2001.010 (-34.5%)
Beta1.05
S&P 52W Chg27.94%
Avg Vol (30d)996.56K
Avg Vol (10d)1.01M
Technical Indicators
RSI (14)47.9
MACD-0.0205
MACD Signal-0.0310
MACD Hist.+0.0105
BB Upper0.7640 USD
BB Middle0.6572 USD
BB Lower0.5503 USD
BB Width32.52%
ATR (14)0.0736 USD
Vol Ratio (20d)0.38x